Skip to main content
. Author manuscript; available in PMC: 2012 Aug 24.
Published in final edited form as: Lancet. 2012 Jan 11;379(9815):537–546. doi: 10.1016/S0140-6736(11)61621-8

Table 4.

Haemodynamic characteristics at diagnosis in patients with confirmed pulmonary hypertension (PH confirmed), according to pulmonary hypertension groups and subgroups

All patients with PH confirmed PH group 3 PH group 1
IPAH or FPAH APAH with CHD
APAH excluding APAH with CHD
All CHD Unrepaired shunt* Repaired shunt Never shunt
Patients with heart catheterisation at diagnosis 357 (99%) 42 (100%) 178 (98%) 115 (100%) 61 (100%) 45 (100%) 9 (100%) 19 (95%)

mRAP 345 (95%) 41 (98%) 172 (95%) 110 (96%) 59 (97%) 43 (96%) 8 (89%) 19 (95%)
 Mean mm Hg (95% CI) 7 (7–8) 7 (6–8) 7 (6–8) 7 (7–8) 7 (6–8) 8 (7–9) 10 (5–14) 8 (6–9)
 p value ·· ·· 0·73 ·· ·· ·· ·· ··

mPAP 357 (99%) 42 (100%) 178 (98%) 115 (100%) 61 (100%) 45 (100%) 9 (100%) 19 (95%)
 Mean mm Hg (95% CI) 58 (56–59) 44 (39–48) 59 (57–62)§ 61 (57–64)§ 64 (59–69) 56 (49–62) 62 (49–75) 53 (45–61)
 p value ·· ·· <0·0001 ·· ·· ·· ·· ··

mPCWP 357 (99%) 42 (100%) 178 (98%) 115 (100%) 61 (100%) 45 (100%) 9 (100%) 19 (95%)
 Mean mm Hg (95% CI) 8 (8–9) 9 (8–9) 8 (8–9) 9 (8–9) 8 (8–9) 9 (8–10) 8 (6–11) 8 (7–9)
 p value ·· ·· 0·99 ·· ·· ·· ·· ··

mSAP 353 (98%) 42 (100%) 176 (97%) 113 (98%) 59 (97%) 45 (100%) 9 (100%) 19 (95%)
 Mean mm Hg (95% CI) 68 (66–69) 62 (58–67) 68 (66–70)§ 68 (65–70)§ 66 (62–70) 68 (64–72) 74 (66–81) 74 (66–82)
 p value ·· ·· 0·04 ·· ·· ·· ·· ··

Cardiac index 348 (96%) 41 (98%) 175 (96%) 110 (96%) 56 (92%) 45 (100%) 9 (100%) 19 (95%)
 Mean L/min/m2 (95% CI) 3·7 (3·5–3·8) 4·2 (3·6–4·8) 3·4 (3·2–3·6)§ 3·9 (3·5–4·3) 3·8 (3·3–4·3) 3·7 (3·2–4·2) 5·4 (2·6–8·3) 4·0 (2·8–5·2)
 p value ·· ·· 0·02 ·· ·· ·· ·· ··

Qp:Qs 357 (99%) 42 (100%) 182 (100%) 110 (96%) 56 (92%) 45 (100%) 9 (100%) 20 (100%)
 Ratio median (IQR) 1·00 (1·0–1·0) 1·00 (1·0–1·0) 1·00 (1·0–1·0) 1·00 (1·0–1·1) 1·03 (0·8–1·5) 1·00 (1·0–1·0) 1·00 (1·0–1·0) 1·00 (1·0–1·0)
 p value ·· ·· 0·92 ·· ·· ·· ·· ··

mPAP:mSAP 353 (98%) 42 (100%) 176 (97%) 113 (98%) 59 (97%) 45 (100%) 9 (100%) 19 (95%)
 Ratio median (IQR) 0·86 (0·7–1·0) 0·69 (0·6–1·0) 0·87 (0·7–1·0)§ 0·92 (0·8–1·0)§ 0·96 (0·9–1·1) 0·84 (0·6–1·0) 0·85 (0·8–1·0) 0·64 (0·5–1·1)
 p value ·· ·· 0·0001 ·· ·· ·· ·· ··

PVRi 357 (99%) 42 (100%) 178 (98%) 115 (100%) 61 (100%) 45 (100%) 9 (100%) 19 (95%)
 Mean WU/m−2 (95% CI) 16·0 (14·9–17·0) 9·8 (8·1–11·5) 17·2 (15·8–18·6)§ 16·3 (14·3–18·3)§ 16·8 (14·6–19·0) 15·0 (11·7–18·3) 19·3 (4·0–34·7) 14·9 (11·1–18·7)
 p value ·· ·· <0·001 ·· ·· ·· ·· ··

SVRi 340 (94%) 41 (98%) 169 (93%) 108 (94%) 54 (89%) 45 (100%) 9 (100%) 19 (95%)
 Mean WU/m−2 (95% CI) 19·7 (18·7–20·8) 15·8 (13·2–18·3) 20·5 (19·2–21·8)§ 19·0 (17·2–20·8)§ 19·0 (16·6–21·4) 18·6 (16·4–20·8) 20·8 (6·4–35·1) 23·4 (14·3–32·4)
 p value ·· ·· 0·002 ·· ·· ·· ·· ··

PVRi:SVRi 340 (94%) 41 (98%) 169 (93%) 108 (94%) 54 (89%) 45 (100%) 9 (100%) 19 (95%)
 Ratio median (IQR) 0·80 (0·6–1·0) 0·66 (0·5–1·0) 0·82 (0·6–1·0)§ 0·79 (0·6–1·0)§ 0·82 (0·6–1·2) 0·79 (0·5–1·0) 0·89 (0·7–1·0) 0·64 (0·4–1·1)
 p value ·· ·· 0·02 ·· ·· ·· ·· ··

Sys ven SO2 202 (56%) 30 (71%) 72 (40%) 88 (77%) 59 (97%) 27 (60%) 2 (22%) 10 (50%)
 Mean % (95% CI) 66% (65–67) 66% (63–70) 66% (64–68) 66% (64–68) 66% (64–69) 65% (61–69) 75% (71–79) 64% (56–72)
 p value ·· ·· 0·96 ·· ·· ·· ·· ··

Sys art SO2 214 (59%) 32 (76%) 78 (43%) 91 (79%) 60 (98%) 29 (64%) 2 (22%) 11 (55%)
 Mean % (95% CI) 91% (90–92) 86% (81–91) 94% (93–95)§ 90% (88–92)§ 88% (87–90) 93% (91–96) 91% (··) 88% (81–96)
 p value ·· ·· <0·0001 ·· ·· ·· ·· ··

Yes responders at AVT 117 (36) 21 (51) 61 (38) 25 (25) 12 (22) 13 (33) 0 (%) 8 (42)

No responders at AVT 206 (64) 20 (49) 100 (62) 74 (75) 42 (78) 26 (67) 6 (100) 11 (58)

APAH excluding APAH with congenital heart disease and groups 4 and 5 are excluded from the analysis. Only patients in the confirmed pulmonary hypertension population are included in the analysis. Patients from pulmonary hypertension groups 4 and 5 (n=3), included in all patients with confirmed pulmonary hypertension, are not depicted separately in this table. APAH=pulmonary arterial hypertension associated with other disorders. IPAH=idiopathic pulmonary arterial hypertension. FPAH=familial pulmonary arterial hypertension. mRAP=mean right atrial pressure. mPAP=mean pulmonary arterial pressure. mSAP=mean systemic arterial pressure. mPCWP=mean pulmonary capillary wedge pressure. PVRI=pulmonary vascular resistance indexed. SVRI=systemic vascular resistance indexed. Qp=pulmonary blood flow. Qs=systemic blood flow. Sys ven SO2=systemic venous oxygen saturation. Sys art SO2=systemic arterial oxygen saturation. AVT=acute pulmonary vasoresponse test as reported by the treating physician (no predefined criteria were used). Data are number (%) unless otherwise specified.

*

Or partial repair.

p value from ANOVA with cause subgroup (1=pulmonary hypertension group 3, 2=IPAH or FPAH, 3=all congenital heart disease) included in the model. APAH excluding APAH with congenital heart disease and groups 4 and 5 are excluded from the analysis. Only patients in the confirmed pulmonary hypertension population are included in the analysis.

p value from Kruskal-Wallis test to assess differences across cause subgroups (1=pulmonary hypertension group 3, 2=IPAH or FPAH, 3=all congenital heart disease).

§

Significantly different from PH Group 3.

Significantly different from IPAH or FPAH.